Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 3
1999 3
2000 4
2001 2
2002 2
2003 3
2004 5
2005 2
2006 5
2007 8
2008 3
2009 4
2010 6
2011 10
2012 10
2013 7
2014 11
2015 15
2016 7
2017 12
2018 6
2019 7
2020 11
2021 16
2022 20
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

164 results
Results by year
Filters applied: . Clear all
Page 1
Cough hypersensitivity and chronic cough.
Chung KF, McGarvey L, Song WJ, Chang AB, Lai K, Canning BJ, Birring SS, Smith JA, Mazzone SB. Chung KF, et al. Among authors: mcgarvey l. Nat Rev Dis Primers. 2022 Jun 30;8(1):45. doi: 10.1038/s41572-022-00370-w. Nat Rev Dis Primers. 2022. PMID: 35773287 Free PMC article. Review.
ERS guidelines on the diagnosis and treatment of chronic cough in adults and children.
Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C, Hilton Boon M, Kantar A, Lai K, McGarvey L, Rigau D, Satia I, Smith J, Song WJ, Tonia T, van den Berg JWK, van Manen MJG, Zacharasiewicz A. Morice AH, et al. Among authors: mcgarvey l. Eur Respir J. 2020 Jan 2;55(1):1901136. doi: 10.1183/13993003.01136-2019. Print 2020 Jan. Eur Respir J. 2020. PMID: 31515408 Free PMC article.
Chronic cough: new insights and future prospects.
Morice A, Dicpinigaitis P, McGarvey L, Birring SS. Morice A, et al. Among authors: mcgarvey l. Eur Respir Rev. 2021 Nov 30;30(162):210127. doi: 10.1183/16000617.0127-2021. Print 2021 Dec 31. Eur Respir Rev. 2021. PMID: 34853095 Free PMC article. Review.
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B, Green SA, Rosa C, Muccino DR, Smith JA; COUGH-1 and COUGH-2 Investigators. McGarvey LP, et al. Lancet. 2022 Mar 5;399(10328):909-923. doi: 10.1016/S0140-6736(21)02348-5. Lancet. 2022. PMID: 35248186 Clinical Trial.
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Smith JA, Kitt MM, Morice AH, Birring SS, McGarvey LP, Sher MR, Li YP, Wu WC, Xu ZJ, Muccino DR, Ford AP; Protocol 012 Investigators. Smith JA, et al. Among authors: mcgarvey lp. Lancet Respir Med. 2020 Aug;8(8):775-785. doi: 10.1016/S2213-2600(19)30471-0. Epub 2020 Feb 25. Lancet Respir Med. 2020. PMID: 32109425 Clinical Trial.
164 results